LNAI

EFFECT - Lunai Bioworks Inc. (0001527728) (Filer)

S-8 POS - Lunai Bioworks Inc. (0001527728) (Filer)

S-8 POS - Lunai Bioworks Inc. (0001527728) (Filer)

POS AM - Lunai Bioworks Inc. (0001527728) (Filer)

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ:LNAI) (the "Company") announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2,500,000. The Company reported a stockholders' deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing

10-K - Lunai Bioworks Inc. (0001527728) (Filer)

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

NT 10-K - Lunai Bioworks Inc. (0001527728) (Filer)

Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targetsSACRAMENTO, Calif., Sept. 22, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease discovery and validation platform. The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent

5.1-fold enrichment using NIH Tox21 data validates structure-based AChE screening as OpenAI and Anthropic highlight growing dual-use AI risksSACRAMENTO, Calif., Sept. 16, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics subsidiary, supporting the development of structure-based screening tools for chemical outputs generated by large language models and other artificial intelligence systems. The study evaluates predicting acetylcholinesterase ("AChE") inhibition directly from molecular structure as a model-agnostic component of the Company's broader chemical-safety and biosecurity s

Correction Updates a Reference Link; No Other Content in the Original Release Has ChangedWILMINGTON, Del. and SACRAMENTO, Calif., Sept. 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI) ("Lunai" or the "Company") today issued this correction to the press release the Company distributed on August 27, 2026 under the headline "Lunai Bioworks (NASDAQ:LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit." The sole correction is to the hyperlink identifying where a copy of the Company's Second Amended Complaint can be found. No other statement in the original release has changed, and the Company is not disclosing any new information in this correction.

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5WILMINGTON, Del. and SACRAMENTO, Calif., Aug. 27, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC). A copy of the Second Amended Complaint is available at https://bit.ly/45Q1MLE.About Lunai Bioworks, Inc.Lunai Bioworks, Inc. (NASDAQ:LNAI) is a Delaware corporati

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering.SACRAMENTO, Calif., and SAN DIEGO, Calif., Aug. 4, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ:LNAI), a biology-first AI drug discovery company, today announced the execution of a Master Collaboration Agreement with BrainStorm Therapeutics Inc. ("BrainStorm"), an AI-powered precision neuroscience company developing disease-modifying therapies using patient-derived human brain organoids and multimodal artificial intelligence.

Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO StatuteWILMINGTON, Del. and SACRAMENTO, Calif., Aug. 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI), an AI driven precision medicine and biodefense company, today announced the filing of its First Amended Complaint in the United States District Court for the District of Delaware naming ten defendants, including three FINRA registered broker dealers, in connection with an alleged coordinated naked short selling scheme that the Company says generated failures to deliver on more than 81% of its outstanding sha

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders,Over the past several months, Lunai Bioworks (NASDAQ:LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology. I would like to update you on developments that have substantially strengthened our position and created multiple pathways for shareholder value creation.A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORMIn April 2026, we secured our first revenue-generating, multi-year defense collaboration through BioSymetrics to deploy our AI-enabled platform for chemical threat assessment.

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and developmentSACRAMENTO, Calif. and SAN DIEGO, May 28, 2026 /PRNewswire/ -- Lunai Bioworks' (NASDAQ:LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the LouLou Foundation.

WASHINGTON, May 22, 2026 /PRNewswire/ -- On Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (NASDAQ:LNAI) (Lunai) to conduct expedited discovery to identify the "John Doe" "naked" short sellers of Lunai common stock on the Nasdaq Stock Market in late 2025 and throughout the first half of 2026. Co-lead counsel, Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from the 'naked' short sellers who have caused real market harm to Lunai and its shareholders."

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

SACRAMENTO, Calif., May 20, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ:LNAI) (the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of 1-for-8 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on May 22, 2026, and the Company's Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 22, 2026, under the existing trading symbol "LNAI."

10-Q - Lunai Bioworks Inc. (0001527728) (Filer)

8-K - Lunai Bioworks Inc. (0001527728) (Filer)

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) are responding to this challenge with next-generation delivery pla